In investing, sometimes the best profitable opportunities are hidden in plain sight. These opportunities come from focusing on what a company does and how it does it. While most investors measure companies by their market capitalization, ZCG look at market segments to see which are most undervalued and have the most growth potential. This article highlights some of the best-undervalued beverage stocks and why they’re the perfect opportunity right now. If you’re interested in getting in on these overlooked but high-potential stocks, keep reading for more details…

Celsius Holdings is a leading developer, manufacturer, and distributor of flavored beverage mixes and concentrates. CELH’s flagship brand is the famous Polar® brand of iced teas and fruit drinks. Polar has been in business for over 80 years and is found in over 80% of households in the United States, making it one of the most recognizable brands in the American beverage landscape.CELH also offers beverage mixes under the PolarZed™ and Polar Pure™ brands.CELH has a market capitalization of $330 million and an enterprise value of $240 million. This makes CELH undervalued, given its strong brand equity, growing revenues, and expanding profit margins. A key growth driver for CELH is its ability to expand its beverage offerings beyond iced teas and juices to include coffee and dairy-based beverages.CELH also has a strategic partnership with J.M. Smucker Co., which specializes in coffee and coffee creamers. CELH has access to a large customer base and a ready distribution system through this partnership.CELH also has a strong balance sheet, which will allow it to continue building its distribution network and investing in new product development.

CCEP is a leading manufacturer and distributor of non-alcoholic ready-to-drink beverages in Russia, Ukraine, and several other countries in Eurasia. CCEP manufactures and distributes carbonated soft drinks, still drinks, energy drinks, and fruit juices. It also produces private label products for other beverage companies. CCEP’s flagship brand is Coca-Cola, which it manufactures and distributes under a license agreement.CCEP has a strong brand, excellent distribution network, and the backing of The Coca-Cola Company, which has 49% ownership in the business. Coca-Cola powers the business with funding and technical expertise and has a long-term strategy for its franchise in Eurasia.

Celldex Therapeutics is a biopharmaceutical company that develops novel immunotherapy product candidates for the treatment of various cancers. CLDX has two stage-ready products that show significant promise for addressing unmet medical needs — CDX-1929 and CDX-2919.CDX-1929 is a new class of immunotherapies that uses the body’s immune system to recognize, attack, and kill cancer cells.CDX-2919 is a monoclonal antibody therapy that blocks cancer cell growth by preventing the release of chemical signals needed for the tumor to grow.CDX-2919 is currently in phase 3 clinical trial for patients with advanced pancreatic cancer. Results from the study are expected to be reported in the third quarter of this year. In addition, CDX-1929 is in phase 2 clinical trial for estrogen receptor-positive breast cancer patients. Results from the study are expected in 2019.

Myovant Sciences is a global specialty biopharmaceutical company focused on women’s health. MYOB has two key products in its pipeline — Letrozole and Terfenadine — and is developing two others — Indomethacin and Suvorexant. Letrozole, the company’s premier product, is used as part of the first-line treatment for postmenopausal women with hormone receptor-positive breast cancer. In addition, MYOB is developing Terfenadine, a product that treats overactive bladder symptoms in postmenopausal women. Indomethacin is a product for women with moderate-to-severe breakthrough pain during cancer treatment. Suvorexant is a product for women with insomnia. MYOB’s most advanced product is Suvorexant, which is in phase 3 clinical trials and has been granted a Breakthrough Therapy Designation by the U.S. Food and Drug Administration.MYOB also has a strong balance sheet, allowing it to continue building out its sales force and investing in new product development.

We hope you enjoyed this article on the best-undervalued beverage stocks. While investors currently overlook these stocks, we expect them to outperform going forward based on their strong growth drivers, market potential, and competitive advantages.

Roberto holds a Master's Degree in Communication and proudly wears his 15 years of direct and managerial experience in intensive Digital Marketing and Financial Analytics. He was the founder of Good Noon, a Digital Marketing Agency awarded by Expertise among the top 10 best marketing agencies in San Francisco in 2020.

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

The Best Stocks , its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

Follow us on Social Media Facebook – YouTube – Twitter

Write for us Finance – Business

Categories Best Stocks to buy now Crypto Dow Jones Today Pre-IPO and Startups Tech stocks Utility Stocks

Data and Tools Quote Target Wealth Converter Dow Jones Today

Best Stocks to Buy Now

We are a financial media dedicated to providing stock recommendations, news, and real-time stock prices.

Get free stock recommendations and real-time news. Our portfolio has returned over 100% in 2020.